Gallet Romain, Tseliou Eleni, Dawkins James, Middleton Ryan, Valle Jackelyn, Angert David, Reich Heidi, Luthringer Daniel, Kreke Michelle, Smith Rachel, Marbán Linda, Marbán Eduardo
From the Cedars-Sinai Heart Institute, Los Angeles, CA (R.G., E.T., J.D., R.M., J.V., D.A., H.R., D.L., M.K., R.S., L.M.); and Capricor Inc, Los Angeles, CA (M.K., R.S., L.M.).
Circ Cardiovasc Interv. 2015 May;8(5). doi: 10.1161/CIRCINTERVENTIONS.115.002391.
Preclinical studies in rodents and pigs indicate that the self-assembling microtissues known as cardiospheres may be more effective than dispersed cardiosphere-derived cells. However, the more desirable intracoronary route has been assumed to be unsafe for cardiosphere delivery: Cardiospheres are large (30-150 μm), raising concerns about likely microembolization. We questioned these negative assumptions by evaluating the safety and efficacy of optimized intracoronary delivery of cardiospheres in a porcine model of convalescent myocardial infarction.
First, we standardized the size of cardiospheres by modifying culture conditions. Then, dosage was determined by infusing escalating doses of cardiospheres in the left anterior descending artery of naive pigs, looking for acute adverse effects. Finally, in a randomized efficacy study, 14 minipigs received allogeneic cardiospheres (1.3 × 10(6)) or vehicle 1 month after myocardial infarction. Animals underwent magnetic resonance imaging before infusion and 1 month later to assess left ventricular ejection fraction, scar mass, and viable mass. In the dosing study, we did not observe any evidence of microembolization after cardiosphere infusion. In the post-myocardial infarction study, cardiospheres preserved LV function, reduced scar mass and increased viable mass, whereas placebo did not. Moreover, cardiosphere decreased collagen content, and increased vessel densities and myocardial perfusion. Importantly, intracoronary cardiospheres decreased left ventricular end-diastolic pressure and increased cardiac output.
Intracoronary delivery of cardiospheres is safe. Intracoronary cardiospheres are also remarkably effective in decreasing scar, halting adverse remodeling, increasing myocardial perfusion, and improving hemodynamic status after myocardial infarction in pigs. Thus, cardiospheres may be viable therapeutic candidates for intracoronary infusion in selected myocardial disorders.
在啮齿动物和猪身上进行的临床前研究表明,被称为心球的自组装微组织可能比分散的源自心球的细胞更有效。然而,人们认为更理想的冠状动脉内途径对于心球递送是不安全的:心球体积较大(30 - 150μm),这引发了对可能发生微栓塞的担忧。我们通过评估在恢复期心肌梗死猪模型中优化的冠状动脉内心球递送的安全性和有效性,对这些负面假设提出了质疑。
首先,我们通过改变培养条件来标准化心球的大小。然后,通过向未处理的猪的左前降支动脉输注递增剂量的心球来确定剂量,观察急性不良反应。最后,在一项随机疗效研究中,14只小型猪在心肌梗死后1个月接受同种异体心球(1.3×10⁶个)或对照剂。在输注前和1个月后对动物进行磁共振成像,以评估左心室射血分数、瘢痕质量和存活心肌质量。在剂量研究中,我们在心球输注后未观察到任何微栓塞的证据。在心肌梗死后研究中,心球保留了左心室功能,减少了瘢痕质量并增加了存活心肌质量,而安慰剂则没有。此外,心球降低了胶原蛋白含量,增加了血管密度和心肌灌注。重要的是,冠状动脉内心球降低了左心室舒张末期压力并增加了心输出量。
冠状动脉内心球递送是安全的。冠状动脉内心球在减少猪心肌梗死后的瘢痕、阻止不良重塑、增加心肌灌注以及改善血流动力学状态方面也非常有效。因此,在心球可能是选定心肌疾病冠状动脉内输注的可行治疗候选物。